Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update (Businesswire) - May 9, 2024 - P1 | N=225 | NCT05047536 | Sponsor: Kezar Life Sciences, Inc. | "KZR-261-101: We are currently enrolling the dose expansion part of the study with a cohort of melanoma patients at a dose level of 60 mg/m2. To date, KZR-261 has shown dose-proportional exposure and no signs of accumulation or altered pharmacokinetics with repeated dosing."
P1 data • Trial status • Melanoma
|